KPIs & Operating Metrics(New)
Growth Metrics

AbbVie (ABBV) Non-Current Deferred Tax Liability (2016 - 2025)

AbbVie (ABBV) has disclosed Non-Current Deferred Tax Liability for 14 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 7.37% to $2.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 billion, a 7.37% decrease, with the full-year FY2025 number at $2.4 billion, down 7.37% from a year prior.
  • Non-Current Deferred Tax Liability was $2.4 billion for Q4 2025 at AbbVie, down from $2.5 billion in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.8 billion in Q1 2021 to a low of $2.0 billion in Q4 2023.
  • A 5-year average of $2.6 billion and a median of $2.6 billion in 2024 define the central range for Non-Current Deferred Tax Liability.
  • Biggest YoY gain for Non-Current Deferred Tax Liability was 292.91% in 2021; the steepest drop was 54.35% in 2021.
  • AbbVie's Non-Current Deferred Tax Liability stood at $3.0 billion in 2021, then decreased by 27.22% to $2.2 billion in 2022, then decreased by 10.87% to $2.0 billion in 2023, then soared by 32.12% to $2.6 billion in 2024, then fell by 7.37% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Non-Current Deferred Tax Liability are $2.4 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.6 billion (Q2 2025).